Novo Nordisk A/S (NVO) vs BeOne Medicines (ONC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BeOne Medicines (ONC) has outperformed Novo Nordisk A/S (NVO) over the past year, losing 0.3% versus a loss of 36.0%. Over five years, ONC leads with a -2.3% price change compared with -25.4% for NVO. Novo Nordisk A/S is the larger company by market cap ($168.54 billion vs $39.83 billion), about 4.2 times the size.
On valuation, Novo Nordisk A/S trades at a lower forward P/E (11.5x vs 34.2x for BeOne Medicines). Novo Nordisk A/S pays a dividend yielding 30.64%, while BeOne Medicines does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVO | ONC |
|---|---|---|
| Share price | $38.18 | $350.13 |
| Market cap | $168.54B | $39.83B |
| 1-day change | -0.21% | -3.82% |
| YTD return | -24.96% | +15.25% |
| 1-year return | -35.95% | -0.27% |
| 5-year return | -25.39% | -2.32% |
| P/E ratio (TTM) | 9.33 | 62.64 |
| Forward P/E | 11.53 | 34.15 |
| EPS (TTM) | $4.09 | $5.59 |
| Dividend yield | 30.64% | 0.00% |
| Annual dividend | $11.70 | $0.00 |
| Revenue (latest FY) | — | $5.34B |
| Revenue growth (YoY) | — | +40.23% |
| Net income (latest FY) | — | $286.93M |
| Gross margin | — | 87.49% |
| Operating margin | — | 8.37% |
| Net margin | — | 5.37% |
| 52-week high | $64.16 | $385.22 |
| 52-week low | $35.12 | $253.95 |
| Distance from 52-week high | -40.49% | -9.11% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +20.67% | +24.30% |
| Average volume | 12.64M | 388.88K |
| Shares outstanding | 3.34B | 104.92M |
| Employees | 66,700 | 12,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Novo Nordisk A/S is about 4.2 times larger than BeOne Medicines by market value ($168.54B vs $39.83B).
- ONC has outperformed NVO by 35.7 percentage points over the past year.
- BeOne Medicines trades at a higher earnings multiple (62.6x vs 9.3x trailing P/E).
- Novo Nordisk A/S offers a meaningfully higher dividend yield (30.64% vs 0.00%).
About Novo Nordisk A/S
NVO stock →Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 66,700 employees
About BeOne Medicines
ONC stock →BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 12,000 employees
NVO vs ONC FAQ
Which is bigger, Novo Nordisk A/S or BeOne Medicines?
Novo Nordisk A/S (NVO) is larger, with a market capitalization of $168.54B compared with $39.83B for BeOne Medicines (ONC).
Which stock has performed better over the past year, NVO or ONC?
ONC returned -0.27% over the past 12 months, compared with -35.95% for NVO (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, NVO or ONC?
NVO has the lower trailing P/E at 9.3, versus 62.6 for ONC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Novo Nordisk A/S or BeOne Medicines?
Novo Nordisk A/S pays a dividend yielding 30.64%, while BeOne Medicines does not currently pay a regular dividend.
Are Novo Nordisk A/S and BeOne Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.